The AJMC® clinical page includes all the published content across, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.

Anti–PD-1 Therapy Likely Leads to Responses in Advanced ICC

August 11th 2022, 11:16pm


The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.

Report Details Rare Case of Warm AIHA Following Epstein-Barr Virus Infection

August 11th 2022, 9:17pm


The case of warm autoimmune hemolytic anemia (AIHA) highlights the potential for life-threatening acute hemolysis if patients do not receive timely treatment.

What We're Reading: Drug Pricing Debate; Judge Rules Against Walgreens; Predicting TBI Outcomes

August 11th 2022, 2:02pm


Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.

Bevacizumab Biosimilar Comparable to Reference Across Disease States

August 10th 2022, 9:15pm


The single-center study evaluated patients across multiple cancers to understand the utilization, safety, and financial outcomes of bevacizumab-awwb vs reference bevavizumab.

SLN Biopsy Promising for Long-term Metastatic Melanoma Control

August 10th 2022, 8:56pm


The usefulness of sentinel lymph node (SLN) biopsy was investigated among patients with melanoma and SLN metastases.

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

August 10th 2022, 3:35pm


Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.

CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup

August 9th 2022, 10:07pm


With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.

Activation, Physical Activity, and Outcomes Among Individuals With T2D

August 9th 2022, 1:00pm


This study presents an integrated, exploratory assessment of physical activity, patient activation, health-related quality of life, and clinical outcomes among older adults with type 2 diabetes (T2D) using survey, wellness, and claims data.

Dr Paolo Caimi Highlights the Need for Access and Better Treatments in DLBCL

August 8th 2022, 9:40pm


Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.

NSCLC Outcomes: Clinical and Non-Clinical Evidence

August 8th 2022, 8:56pm


An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.